Product
LUMIGAN
Aliases
LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Name
LUMIGAN
INN Name
bimatoprost
FDA Approved
Yes
3 clinical trials
1 organization
5 indications
1 document
Indication
Open-angle GlaucomaIndication
ocular hypertensionIndication
open-angle glaucomaIndication
GlaucomaIndication
Open-AngleClinical trial
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)Status: Completed, Estimated PCD: 2022-05-14
Clinical trial
A Randomized ( 1:1), Double-Masked, Multi-Center, Two-Treatment, Single-Period, Parallel Design, Mutiple Dose Bioequivalence Study With Clinical End-Point of Bimatoprost Ophthalmic Solution 0.01% of Mankind Pharma Limited With LUMIGAN (Bimatoprost Ophthalmic Solution) 0.01% of Allergan, Inc., in Subjects With Chronic Open-Angle Glaucoma Or Ocular Hypertension in Both EyesStatus: Completed, Estimated PCD: 2022-08-11
Document
DailyMed Label: LUMIGANOrganization
Allergan, Inc.